Prostate Ultrahypofractionation - Rising to Challenges Presents Opportunities in the COVID-19 Era
- PMID: 33158724
- PMCID: PMC7610090
- DOI: 10.1016/j.clon.2020.10.012
Prostate Ultrahypofractionation - Rising to Challenges Presents Opportunities in the COVID-19 Era
References
-
- Lehrer E.J., Kishan A.U., James B.Y., Trifiletti D.M., Showalter T.N., Ellis R. Ultrahypofractionated vs hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: a systematic review and meta-analysis of phase III randomized trials. Radiother Oncol. 2020;148:235–242. doi: 10.1016/j.radonc.2020.04.037. - DOI - PubMed
-
- Brand D.H., Tree A.C., Ostler P., van der Voet H., Loblaw A., Chu W. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20(11):1531–1543. doi: 10.1016/S1470-2045(19)30569-8. - DOI - PMC - PubMed
-
- NHS digital: National Cancer waiting times monitoring dataset guidance - Version 11.0. September 2020. https://digital.nhs.uk/data-and-information/data-collections-and-data-se...
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
